DTGM FUSION PROTEIN IND8153 IN ACUTE MYELOID LEUKEMIA

$0M01FY2000RRNIH

Wake Forest University, Winston Salem NC

Investigators

Linked publications & trials

Paper 39057616 Paper 38690907 Paper 38336201 Paper 37726016 Paper 37722552 Paper 37662265 Paper 37105408 Paper 36946148 Paper 36940238 Paper 36066606 Paper 34990411 Paper 34166655 Paper 33478957 Paper 33402707 Paper 32978526 Paper 32839606 Paper 32795586 Paper 32475043 Paper 32446491 Paper 32372009 Paper 32346123 Paper 31869403 Paper 31783400 Paper 31691959 Paper 31659325 Paper 31604627 Paper 31427096 Paper 31229956 Paper 31092297 Paper 30737489 Paper 30698716 Paper 30487263 Paper 30404738 Paper 30112655 Paper 30062831 Paper 29920834 Paper 29872859 Paper 29846325 Paper 29768320 Paper 29691896 Paper 29635402 Paper 29538362 Paper 29520864 Paper 29461649 Paper 29369937 Paper 29325163 Paper 28982710 Paper 28574979 Paper 28562255 Paper 28403949 Paper 28283553 Paper 28279433 Paper 28199816 Paper 28087371 Paper 27918534 Paper 27896979 Paper 27765481 Paper 27636897 Paper 27632775 Paper 27615667 Paper 27410922 Paper 27392821 Paper 27356020 Paper 27342958 Paper 27244849 Paper 27179829 Paper 27142425 Paper 27117196 Paper 27082885 Paper 27032714 Paper 26992407 Paper 26895876 Paper 26874390 Paper 26746456 Paper 26739237 Paper 26720295 Paper 26693712 Paper 26658788 Paper 26608545 Paper 26569652 Paper 26546809 Paper 26516117 Paper 26515258 Paper 26348753 Paper 26305897 Paper 26283757 Paper 26206811 Paper 26196951 Paper 26195573 Paper 26185004 Paper 26112621 Paper 26080344 Paper 25982112 Paper 25963022 Paper 25961151 Paper 25868431 Paper 25811948 Paper 25782717 Paper 25750186 Paper 25737484

Abstract

The purpose of this study is to attempt to determine the maximal tolerable dose of DTGM fusion protein when given through the veins to patients with acute myeloid lukemia. Groups of 3 patients will be given the same doses of DTGM. If the drug doses are tolerated well be the group, the next group of 3 patients will recieve slightly higher doses. DTGM is a promising drug that we have developed in our laboratory, which has shown significant anti-leukemia activity both in test tubes and animals, but has not previously been tested in patients. We are studying the safety and efficacy of this drug in patients with relapsed/refractory acute myeloid leukemia.

View original record on NIH RePORTER →